We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Adam H. Golden

Partner
New York

Adam H. Golden

Head of the Corporate Practice Group in New York, Adam Golden advises life sciences companies on their most important transactions. Clients turn to Adam for his dual skillset, which combines his strengths as an M&A and corporate lawyer, with those of an IP transactions lawyer. This enables him to represent pharmaceutical, biotech, and medical device companies in the full scope of transactions that are common to this sector.

Over his career, Adam has advised clients on M&A, capital markets transactions, license and collaboration deals, venture capital financings, and commercial transactions. Frequently, clients seek his advice on hybrid transactions such as M&A transactions with back-end milestone payments, options to acquire companies or technology, and product divestitures. He also advises clients on the transition service, manufacturing and supply, and other operational agreements that often accompany these transactions.

Adam is recognized as a leading practitioner in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, and IAM Patent 1000.

"Adam Golden is a respected corporate and transactional attorney with an impressive level of experience in acting for pharmaceutical, biotechnology and medical device companies."

Chambers USA

Representative experience

Valeant on the sale of Dendreon Pharmaceuticals, Inc. to the Sanpower Group Co., Ltd for $820m. 

Chase Pharmaceuticals on its sale to Allergan for up to $1bn.

Novartis in its $665m acquisition of Selexys Pharmaceuticals, a developer of therapeutics to treat pain associated with certain blood and inflammatory disorders like sickle cell disease.

Allergan on its $40.5bn generics divestiture to Teva Pharmaceuticals.

Novartis in its acquisition of Encore Vision, focused on the development of a novel treatment in presbyopia.

Alcon in the acquisition of Transcend Medical, Inc., developer of technologies for the treatment of glaucoma.

Pfizer on its immuno-oncology research collaboration with Western Oncolytics to investigate novel oncolytic virus technology.

Nektar Therapeutics on an exclusive license agreement with Daiichi Sankyo Europe for the commercialization of ONZEALD™ within the European Economic Area, Switzerland, and Turkey.

Allergan on an exclusive license agreement with Cardiome Pharma Corp. for the commercialization of XYDALBA™ in the U.K., EU, Middle East, and Canada.


Novartis in an immune-oncology collaboration with Surface Oncology.  

Sanofi in its $2.2bn global collaboration with Regeneron Pharmaceuticals to develop novel antibody-based immuno-oncology treatments.

Novartis in the acquisition of rights from GSK to Arzerra® (ofatumumab) for auto-immune indications for more than $1bn.

Novartis in connection with its landmark portfolio transformation transactions with GSK and Eli Lilly worth more than $23bn.


Education and admissions

Education

  • J.D., New York University School of Law, 1990
  • A.B., Princeton University, 1986

Bar admissions and qualifications

  • New York
  • Massachusetts

2015-2017

Life Sciences (Global-wide)

Chambers Global

2014-2017

Life Sciences: Corporate/Commercial (Nationwide)

Chambers USA

2014-2017

Healthcare: Life Sciences, Leading Lawyer

Legal 500 US

2017

M&A/Corporate and Commercial: M&A: Large Deals ($1bn+)

Legal 500 US

2012-2016

Life Sciences Star - Finance & Transactional

LMG Life Sciences

2016

Life Sciences - Transactional

Who's Who Legal

2012-2016

The World's Leading Patent Practitioners

IAM Patent 1000

Latest thinking and events

View More
Loading data